IHE ETF

iShares U.S. Pharmaceuticals ETF is a pharmaceutical ETF offered by iShares, featuring an expense ratio of 0.39% and over $500 million in assets under management. In Q3, the healthcare sector reported earnings that exceeded expectations (+9.3%) and provided strong guidance for CV 2025, according to FactSet. The IHE prices are down 10% from their all-time high, with the next point of control 20% lower, while the maximum drawdown in the past 10 years was 40%.

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.

Launched on 05/01/2006, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

IHE invests in large-cap U.S. pharmaceutical stocks with solid long-term growth outlook but high concentration risk. IHE's fund price has been steady with a positive trend in 2024, but its elevated valuation may not make it a good buy currently. Despite being a defensive play in an economic recession, IHE can still experience significant declines due to market sentiment.

The iShares U.S. Pharmaceuticals ETF (IHE) was established on May 1, 2006, and is an exchange traded fund that aims to provide comprehensive coverage of the Healthcare - Pharma sector through passive management.

Bargain hunting in a market where the S&P 500 is at record levels may seem like a daunting task, but it's not impossible.

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund launched on 05/01/2006.

Investors seeking momentum may have iShares U.S. Pharmaceuticals ETF IHE on radar now. The fund recently hit a new 52-week high.

The S&P 500 has been hovering around an all-time high. The chart indicates that, on average, investments made at record highs tend to perform better over the next five years, as quoted on Yahoo Finance.